连续2天盘中涨逾3%！资金回流提速，港股通创新药ETF（520880）掀开创新药反弹新周期

Core Viewpoint - The Hong Kong stock market experienced an overall pullback, but the innovative drug sector saw significant gains, with BeiGene rising over 7% to reach a three-year high, and the Hong Kong Stock Connect Innovative Drug ETF (520880) continuing to rise by 3% despite the market downturn [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw its fund size exceed 2 billion yuan for the first time on November 3, marking a 392% increase since its launch on July 7 [1] - The innovative drug index has historically experienced an average pullback duration of 30-40 days, with a typical decline of around 20% [1] - The current adjustment has lasted nearly a quarter, with the index down over 20%, indicating a potential high-probability entry point for investors [1] Group 2: Industry Trends - The trend of Chinese innovative drugs going global is clear, supported by ongoing drug review reforms and favorable policies [1] - The Chinese innovative drug industry has entered its 2.0 era, shifting from "importing and imitating" to "innovating and exporting" [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025221) track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively invests in innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [2]